In Jan, 2024, we announced the commissioning of a new peptide manufacturing plants at the Taixing site in China. Commissioning the peptide plant at the Taixing site marks its official launch as the newest and largest of WuXi STA’s five API production sites.
Spanning a total area of 169 acres, the Taixing site is designed to manufacture a range of synthetic molecules, including small molecules, peptides, oligonucleotides, and conjugates. The phase I construction includes nine plants with the total reactor volume exceeding 1,000 m3, including a dedicated plant for API clean rooms. Once Taixing site Phase I is fully operational in 2025, the company’s total reactor volume for small molecule API and intermediate manufacturing will surpass 4,000 m3.
